Chembio Diagnostics
Market Cap
US$100.8m
Last Updated
2020/10/27 00:41 UTC
Data Sources
Company Financials +
Executive Summary
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet with limited growth.
Similar Companies
Share Price & News
How has Chembio Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CEMI's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
1.8%
CEMI
0.09%
US Medical Equipment
-1.1%
US Market
1 Year Return
-9.1%
CEMI
22.2%
US Medical Equipment
15.6%
US Market
Return vs Industry: CEMI underperformed the US Medical Equipment industry which returned 24.8% over the past year.
Return vs Market: CEMI underperformed the US Market which returned 17.8% over the past year.
Shareholder returns
| CEMI | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.8% | 0.09% | -1.1% |
| 30 Day | 7.0% | 6.5% | 4.2% |
| 90 Day | -1.2% | 5.8% | 6.3% |
| 1 Year | -9.1%-9.1% | 23.3%22.2% | 18.2%15.6% |
| 3 Year | -16.7%-16.7% | 75.4%70.7% | 39.6%30.4% |
| 5 Year | 1.6%1.6% | 138.9%120.1% | 79.5%59.2% |
Price Volatility Vs. Market
How volatile is Chembio Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Investors Who Bought Chembio Diagnostics (NASDAQ:CEMI) Shares Five Years Ago Are Now Up 18%2 months ago | Simply Wall St
Is Chembio Diagnostics (NASDAQ:CEMI) A Risky Investment?3 months ago | Simply Wall St
Could The Chembio Diagnostics, Inc. (NASDAQ:CEMI) Ownership Structure Tell Us Something Useful?Valuation
Is Chembio Diagnostics undervalued compared to its fair value and its price relative to the market?
2.6x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CEMI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CEMI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CEMI is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: CEMI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CEMI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CEMI is good value based on its PB Ratio (2.6x) compared to the US Medical Equipment industry average (4.1x).
Next Steps
Future Growth
How is Chembio Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
45.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CEMI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CEMI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CEMI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CEMI's revenue (26% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: CEMI's revenue (26% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CEMI's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Chembio Diagnostics performed over the past 5 years?
-24.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CEMI is currently unprofitable.
Growing Profit Margin: CEMI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CEMI is unprofitable, and losses have increased over the past 5 years at a rate of 24.4% per year.
Accelerating Growth: Unable to compare CEMI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CEMI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.9%).
Return on Equity
High ROE: CEMI has a negative Return on Equity (-52.96%), as it is currently unprofitable.
Next Steps
Financial Health
How is Chembio Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: CEMI's short term assets ($53.9M) exceed its short term liabilities ($14.3M).
Long Term Liabilities: CEMI's short term assets ($53.9M) exceed its long term liabilities ($24.9M).
Debt to Equity History and Analysis
Debt Level: CEMI's debt to equity ratio (46.4%) is considered high.
Reducing Debt: Insufficient data to determine if CEMI's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CEMI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CEMI has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 30.3% each year.
Next Steps
Dividend
What is Chembio Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CEMI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CEMI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CEMI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CEMI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CEMI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.8yrs
Average management tenure
CEO
Richard Eberly (59 yo)
0.58
Tenure
Mr. Richard L. Eberly serves as the President and Chief Executive Officer at Chembio Diagnostics, Inc. since March 16, 2020 and has been its Director since May 02, 2020. He joined Chembio in March, 2020. H ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive VP & CFO | 2.83yrs | US$346.94k | 0.43% $ 437.8k | |
| Executive VP | 16.75yrs | US$409.98k | 0.54% $ 543.9k | |
| President | 0.58yr | no data | no data | |
| Vice President of Global Operations | 0.75yr | no data | no data | |
| Vice President of Sales & Marketing | 0.33yr | no data | no data | |
| Research Director of Chembio Diagnostic Systems Inc | no data | US$106.37k | no data |
0.8yrs
Average Tenure
53yo
Average Age
Experienced Management: CEMI's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 0.58yr | no data | no data | |
| Independent Director | 2.17yrs | US$40.50k | 0.039% $ 38.9k | |
| Independent Director | 2.42yrs | US$44.50k | 0.19% $ 188.9k | |
| Independent Chairperson | 6.58yrs | US$73.50k | 0.40% $ 403.8k |
2.3yrs
Average Tenure
61.5yo
Average Age
Experienced Board: CEMI's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.8%.
Top Shareholders
Company Information
Chembio Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Chembio Diagnostics, Inc.
- Ticker: CEMI
- Exchange: NasdaqCM
- Founded: 1985
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$100.808m
- Shares outstanding: 20.16m
- Website: https://chembio.com
Number of Employees
Location
- Chembio Diagnostics, Inc.
- 555 Wireless Boulevard
- Hauppauge
- New York
- 11788
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CEMI | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Oct 2000 |
| D9IA | BST (Boerse-Stuttgart) | Yes | Common Stock | DE | EUR | Oct 2000 |
Biography
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers t ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/27 00:41 |
| End of Day Share Price | 2020/10/26 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.